This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Effects of Ramipril Combined With Candesartan

This study has been completed.
Information provided by:
Gachon University Gil Medical Center Identifier:
First received: July 25, 2006
Last updated: NA
Last verified: March 2006
History: No changes posted
we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.

Condition Intervention Phase
Hypertension Drug: ramipril, candesartan Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients

Resource links provided by NLM:

Further study details as provided by Gachon University Gil Medical Center:

Primary Outcome Measures:
  • comparison of endothelium-dependent dilation among the 3 treatment schemes

Estimated Enrollment: 40
Study Start Date: August 2003
Estimated Study Completion Date: March 2006
Detailed Description:
Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).

Ages Eligible for Study:   35 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with mild to moderate hypertension

Exclusion Criteria:

  • We will exclude patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00356395

Sponsors and Collaborators
Gachon University Gil Medical Center
Principal Investigator: Kwang K Koh, MD Cardiology, Gil Heart Center, Gachon Medical School
  More Information Identifier: NCT00356395     History of Changes
Other Study ID Numbers: 2003-008
Study First Received: July 25, 2006
Last Updated: July 25, 2006

Keywords provided by Gachon University Gil Medical Center:
endothelial function, insulin resistance, adipocytokines

Additional relevant MeSH terms:
Candesartan cilexetil
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists processed this record on June 23, 2017